@drtimos.bsky.social

13 hours ago

ACC 2026 Preview: Key Cardiology Highlights to Watch ACC 2026 at a Glance Get ready for ACC 2026. LucidQuest’s preview highlights the most important clinical and AI-powered developments […] The post ACC 2026 Preview: Key Cardiology Highlights to Watch appeared first on LucidQuest Ventures.

LucidQuest Views >>> ACC 2026 Preview: Key Cardiology Highlights to Watch Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

16 hours ago

Trending in Obesity: Imcivree FDA Approval, Semaglutide Generics and more This edition highlights major developments in obesity treatment, including a new FDA approval for Imcivree in acquired hypothalamic obesity and progress toward generic semaglutide in global markets. Additional updates span Phase 2 and Phase 3 milestones, early-stage clinical advancements, and mixed data readouts. Key players continue to expand beyond traditional GLP-1 approaches, while evolving access dynamics may reshape treatment availability and pricing across multiple regions.

LucidQuest YouTube > Trending in Obesity: Imcivree FDA Approval, Semaglutide Generics and more: This edition highlights major developments in obesity treatment, including a new FDA approval for Imcivree in acquired hypothalamic obesity and progress toward… Subscribe for more! #LucidQuest #PharmaCI

@drtimos.bsky.social

17 hours ago

Endocrinology Today—March 31, 2026 This week’s Endocrinology update highlights regulatory progress, access expansion, digital care initiatives, device innovation, and strategic partnerships across metabolic and […] The post Endocrinology Today—March 31, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Endocrinology Today—March 31, 2026 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

17 hours ago

Obesity Today—March 31, 2026 This week’s Obesity update highlights regulatory progress, advancing late-stage development, mixed clinical readouts, pricing shifts, and continued investment in next-generation […] The post Obesity Today—March 31, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Obesity Today—March 31, 2026 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

23 hours ago

Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804 Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804 Professional audiences only. Not investment […] The post Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

1 day ago

Hematology Today—March 30, 2026 This week’s Hematology update highlights regulatory progress, evolving treatment delivery models, advancing clinical pipelines, and strategic expansion across blood disorders. […] The post Hematology Today—March 30, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Hematology Today—March 30, 2026 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

1 day ago

Trending in Oncology: Imfinzi EU Approval, Zepzelca CHMP Backing and more This oncology update highlights major regulatory and clinical developments across global markets. Key updates include EU approval of Imfinzi in early gastric cancer and a positive CHMP recommendation for Zepzelca in small cell lung cancer. Additional progress spans guideline changes in bladder cancer, NDA resubmission for glioma imaging, Fast Track designation in adenoid cystic carcinoma, and multiple EMA validations and FDA alignments supporting late-stage oncology pipelines

LucidQuest YouTube > Trending in Oncology: Imfinzi EU Approval, Zepzelca CHMP Backing and more: This oncology update highlights major regulatory and clinical developments across global markets. Key updates include EU approval of Imfinzi in early gastric… Subscribe for more! #LucidQuest #PharmaCI

@drtimos.bsky.social

1 day ago

Oncology Today—March 30, 2026 This week’s Oncology update highlights regulatory momentum, late-stage clinical progress, and filing activity across lung, bladder, gastrointestinal, pancreatic, breast, and […] The post Oncology Today—March 30, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Oncology Today—March 30, 2026 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

1 day ago

AI in Healthcare and Digital Health Today—March 30, 2026 This week’s Artificial Intelligence and Digital Health update highlights regulatory milestones, expanding CNS and cardiovascular AI pipelines, growing wearable-driven insights, […] The post AI in Healthcare and Digital Health Today—March 30, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> AI in Healthcare and Digital Health Today—March 30, 2026 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

1 day ago

Lucid Diligence Brief: InSilico Medicine and Lilly global partnership Lucid Diligence Brief: InSilico Medicine and Lilly global partnership Professional audiences only. Not investment research or advice. UK readers: for […] The post Lucid Diligence Brief: InSilico Medicine and Lilly global partnership appeared first on LucidQuest Ventures.

LucidQuest Views >>> Lucid Diligence Brief: InSilico Medicine and Lilly global partnership Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

2 days ago

Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics Professional audiences only. Not investment research or advice. UK readers: for persons […] The post Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics appeared first on LucidQuest Ventures.

LucidQuest Views >>> Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

3 days ago

Trending in Health Mobile Apps in H2 2025: Downloads, Rankings and More Across therapy areas in H2 2025, mobile health apps largely centered on tracking and self-management rather than validated clinical integration. Cardiovascular, diabetes, and respiratory ecosystems showed scale and routine use but limited decision support. Neurology areas including Alzheimer’s, Parkinson’s, migraine, and multiple sclerosis remained monitoring-focused. Oncology apps supported patients alongside care, while arthritis, psoriasis, kidney health, and IBD emphasized symptom logging. Hemophilia showed credibility but narrow scope. Mental health apps remained consumer-oriented, with validation and treatment optimization still limited.

LucidQuest YouTube > Trending in Health Mobile Apps in H2 2025: Downloads, Rankings and More: Across therapy areas in H2 2025, mobile health apps largely centered on tracking and self-management rather than validated clinical integration. Cardiovascular,… Subscribe for more! #LucidQuest #PharmaCI

@drtimos.bsky.social

3 days ago

Lucid Diligence Brief: AstraZeneca’s tozorakimab meets primary endpoint in COPD Lucid Diligence Brief: AstraZeneca’s tozorakimab meets primary endpoint in COPD Professional audiences only. Not investment research or advice. UK readers: […] The post Lucid Diligence Brief: AstraZeneca’s tozorakimab meets primary endpoint in COPD appeared first on LucidQuest Ventures.

LucidQuest Views >>> Lucid Diligence Brief: AstraZeneca’s tozorakimab meets primary endpoint in COPD Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

4 days ago

Trending in Public Health: CAR-T in MS, Cholesterol Guidelines and more. This edition highlights early-stage CAR-T therapy trials in multiple sclerosis and updated cholesterol management guidance emphasizing earlier intervention and improved risk assessment. It also covers large-scale child health research through GenV, new insights into aging biology, delayed paternal mental health risks, and evidence linking chronic inflammation and infections to long-term disease outcomes. Additional discussion explores the ongoing debate around social media use and its potential health impacts.

LucidQuest YouTube > Trending in Public Health: CAR-T in MS, Cholesterol Guidelines and more.: This edition highlights early-stage CAR-T therapy trials in multiple sclerosis and updated cholesterol management guidance emphasizing earlier intervention and… Subscribe for more! #LucidQuest #PharmaCI

@drtimos.bsky.social

4 days ago

Public Health Today—March 27, 2026 This weekly update in Public Health highlights new population-level research, observational registry findings, mechanistic insights, and clinical trial data. Coverage […] The post Public Health Today—March 27, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Public Health Today—March 27, 2026 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

4 days ago

Lucid Diligence Brief: Pinnacle Medicines $89 million Series B Lucid Diligence Brief: Pinnacle Medicines $89 million Series B Professional audiences only. Not investment research or advice. UK readers: for […] The post Lucid Diligence Brief: Pinnacle Medicines $89 million Series B appeared first on LucidQuest Ventures.

LucidQuest Views >>> Lucid Diligence Brief: Pinnacle Medicines $89 million Series B Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

4 days ago

Respiratory Today—March 27, 2026 This week’s Respiratory update highlights clinical trial progress, regulatory approvals, product launches, and emerging modalities across infectious and chronic lung […] The post Respiratory Today—March 27, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Respiratory Today—March 27, 2026 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

4 days ago

Vaccines Today—March 27, 2026 This week’s Vaccines and Infectious Disease update highlights clinical trial progress, regulatory milestones, manufacturing partnerships, financing activity, and geographic expansion […] The post Vaccines Today—March 27, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Vaccines Today—March 27, 2026 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

5 days ago

Trending in Cardiovascular: JenaValve Approval, Asundexian data and more Recent cardiovascular developments highlight key regulatory approvals, clinical trial progress, and innovation in stroke and structural heart care. JenaValve secured FDA approval for its Trilogy device in severe aortic regurgitation, while asundexian showed positive results in secondary stroke prevention. Additional updates include Medtronic’s expanded indication for OmniaSecure, new stroke devices from Johnson & Johnson, Emboline’s financing milestone, and growing adoption of AI in TAVR planning and cardiac ultrasound training.

LucidQuest YouTube > Trending in Cardiovascular: JenaValve Approval, Asundexian data and more: Recent cardiovascular developments highlight key regulatory approvals, clinical trial progress, and innovation in stroke and structural heart care. JenaValve… Subscribe for more! #LucidQuest #PharmaCI

@drtimos.bsky.social

5 days ago

Cell and Gene Therapy Today—March 26, 2026 This week’s Gene and Cell Therapy update highlights regulatory approvals, clinical progress, manufacturing investments, and expanding commercialization and partnership activity. […] The post Cell and Gene Therapy Today—March 26, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Cell and Gene Therapy Today—March 26, 2026 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

5 days ago

Rare Diseases Update – 26 Mar 2026: Dupixent Japan Approval, OTC Gene Therapy Phase 3 and More This Rare Diseases update covers key regulatory actions, clinical trial progress, gene therapy developments, and rare disease treatment advances reported over the past two weeks. In this episode: 🧬 Venglustat gains FDA Breakthrough Therapy designation for Gaucher disease 🎯 GSK ADC receives orphan designation for small-cell lung cancer in Japan 🧴 Dupixent approved in Japan for bullous pemphigoid 💊 PANTHERx selected as exclusive specialty pharmacy for KYGEVVI 🧬 Sarepta plans regulatory submissions for Duchenne exon-skipping drugs 🧬 Otsuka presents PKU data for repinatrabit and advances Phase 3 trial 🧴 QRX003 receives FDA Fast Track for Netherton syndrome 🧬 Ultragenyx gene therapy meets Phase 3 endpoint in OTC deficiency 📢 Stay Ahead in Rare Diseases Research! ✅ Like, share, and subscribe for future updates on Rare Diseases ✅ Visit www.lqventures.com for expert healthcare insights and consulting services. ✅ Contact LucidQuest at info@lqventures.com for strategic guidance on Rare Diseases innovations and clinical research. 🔔 Turn on notifications so you never miss an update! #RareDiseases #GeneTherapy #FDA #ClinicalTrials #Biotech #DrugDevelopment #PharmaNews #LucidQuest

LucidQuest YouTube > Rare Diseases Update – 26 Mar 2026: Dupixent Japan Approval, OTC Gene Therapy Phase 3 and More: This Rare Diseases update covers key regulatory actions, clinical trial progress, gene therapy developments, and rare disease treatment… Subscribe for more! #LucidQuest #PharmaCI

@drtimos.bsky.social

5 days ago

Rare Diseases Today—March 26, 2026 This week’s Rare Diseases update highlights regulatory designations, new approvals, advancing clinical programs, and expanding access partnerships across neurological, genetic, […] The post Rare Diseases Today—March 26, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Rare Diseases Today—March 26, 2026 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

5 days ago

Cardiovascular Today—March 26, 2026 This week’s Cardiovascular update highlights regulatory approvals, device innovation, AI-enabled care advancements, and emerging clinical and observational data across heart […] The post Cardiovascular Today—March 26, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Cardiovascular Today—March 26, 2026 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

5 days ago

Lucid Diligence Brief: MSD to acquire Terns Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not investment research or advice. UK readers: for persons under […] The post Lucid Diligence Brief: MSD to acquire Terns appeared first on LucidQuest Ventures.

LucidQuest Views >>> Lucid Diligence Brief: MSD to acquire Terns Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

6 days ago

Trending in Immunology: Lynavoy Approval and ICOTYDE Psoriasis and more This update highlights key developments in immunology, including FDA approvals for Lynavoy in cholestatic pruritus associated with primary biliary cholangitis and ICOTYDE as a novel oral IL-23 receptor therapy for plaque psoriasis. Additional updates include EU approval of Imfinzi in early gastric cancer, pediatric expansion for Cosentyx in hidradenitis suppurativa, and regulatory progress for ILUMYA in psoriatic arthritis. Pipeline momentum continues with accelerated clinical timelines and a notable licensing deal between Sanofi and Kali Therapeutics.

LucidQuest YouTube > Trending in Immunology: Lynavoy Approval and ICOTYDE Psoriasis and more: This update highlights key developments in immunology, including FDA approvals for Lynavoy in cholestatic pruritus associated with primary biliary cholangitis and… Subscribe for more! #LucidQuest #PharmaCI

@drtimos.bsky.social

6 days ago

Neuroscience Today—March 25, 2026 This week’s Neuroscience update highlights commercial launches, manufacturing partnerships, preclinical progress, portfolio expansion, health economics evidence, and updated care guidance […] The post Neuroscience Today—March 25, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Neuroscience Today—March 25, 2026 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

6 days ago

Immunology Today—March 25, 2026 This week’s Immunology update highlights regulatory progress, dermatology research platform expansion, and continued partnership activity across autoimmune and immune-mediated diseases. […] The post Immunology Today—March 25, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Immunology Today—March 25, 2026 Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

6 days ago

Immunology Update – 25 Mar 2026: Lynavoy PBC Approval, ICOTYDE in Psoriasis and More This Immunology update covers key regulatory approvals, clinical progress, and pipeline developments across dermatology, hepatology, and autoimmune diseases, highlighting innovation in oral therapies, pediatric expansion, and strategic partnerships. Key Highlights: 🧬 Imfinzi expands in early gastric cancer 🧒 Cosentyx adds pediatric hidradenitis suppurativa 🧪 Spyre pulls SKYWAY RA readout forward 📄 ILUMYA PsA filing enters FDA review 🩺 Lynavoy becomes first US PBC itch medicine 💊 ICOTYDE opens oral IL-23R option in psoriasis 🧴 Sonoma launches Aquanil AD with Persōn & Covey 🤝 Sanofi licenses KT501 from Kali Therapeutics Chapters: 0:00 Introduction 0:08Imfinzi expands in early gastric cancer 0:36 Cosentyx adds pediatric hidradenitis suppurativa 1:03 Spyre pulls SKYWAY RA readout forward 1:30 ILUMYA PsA filing enters FDA review 1:51 Lynavoy becomes first US PBC itch medicine 2:19 ICOTYDE opens oral IL-23R option in psoriasis 2:52 Sonoma launches Aquanil AD with Persōn & Covey 3:17 Sanofi licenses KT501 from Kali Therapeutics 3:40 How to reach us 📢 Stay Ahead in Immunology Research! ✅ Like, share, and subscribe for future updates on Immunology. ✅ Visit www.lqventures.com for expert healthcare insights and consulting services. ✅ Contact LucidQuest at info@lqventures.com for strategic guidance on Immunology innovations and clinical research. 🔔 Turn on notifications so you never miss an update! #Immunology #FDA #ClinicalTrials #PharmaNews #Biotech #Dermatology #Autoimmune #DrugDevelopment #LucidQuest

LucidQuest YouTube > Immunology Update – 25 Mar 2026: Lynavoy PBC Approval, ICOTYDE in Psoriasis and More: This Immunology update covers key regulatory approvals, clinical progress, and pipeline developments across dermatology, hepatology, and autoimmune… Subscribe for more! #LucidQuest #PharmaCI

@drtimos.bsky.social

6 days ago

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal Professional audiences only. Not investment research […] The post Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal appeared first on LucidQuest Ventures.

LucidQuest Views >>> Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal Comment below! #LucidQuest #PharmaCI

@drtimos.bsky.social

1 week ago

Trending in Endocrinology: Retatrutide, Generic Semaglutide and more This biweekly endocrinology recap highlights Eli Lilly’s positive Phase 3 retatrutide topline results, the launch of generic semaglutide in India by Eris and Natco, and early clinical progress for GentiBio’s GNTI-122 in type 1 diabetes. It also covers feasibility data for Insulet’s fully closed-loop insulin system, Zydus’ AI-enabled CGM launch, Endogenex’s 48-week REGENT-1 data, new sotagliflozin analysis from Lexicon, and a cell therapy collaboration between NewcelX and Eledon.

LucidQuest YouTube > Trending in Endocrinology: Retatrutide, Generic Semaglutide and more: This biweekly endocrinology recap highlights Eli Lilly’s positive Phase 3 retatrutide topline results, the launch of generic semaglutide in India by Eris and Natco,… Subscribe for more! #LucidQuest #PharmaCI